AbilityPharma’s IBRILATAZAR (ABTL0812) doubles overall survival in patients with squamous non-small cell lung cancer

by AbilityPharma

The trial evaluated the safety and efficacy of ibrilatazar (ABTL0812) combined with paclitaxel/carboplatin in 40 patients with stage III/IV squamous non-small cell lung cancer (sq-NSCLC), at 6 leading...

AbilityPharma receives WHO approval for its ABTL0812 anticancer drug to be named IBRILATAZAR

by AbilityPharma

2 years ago
ibrilatazar, AbilityPharma, ABTL0812

AbilityPharma announces that the World Health Organization (WHO) has recommended ABTL0812, a first-in-class oral drug for cancer treatment that causes selective death of cancer cells through autophagy...

AGC Pharma Chemicals y AbilityPharma trabajan juntos en la producción de un tratamiento innovador para el cáncer de páncreas

by AbilityPharma

2 years ago
principio activo farmacéutico (API), ABTL081, AbilityPharma, Pharma Chemicals, AGC Pharma Chemicals

Con este acuerdo, la biofarmacéutica española AbilityPharma inicia la fabricación de su fármaco principal ABTL0812 para administrar a pacientes con cáncer de páncreas en el marco del ensayo clí...

AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer

by AbilityPharma

2 years ago
AbilityPharma, ABTL0812, CTI Life Sciences Fund, Inveready, EIC Fund

AbilityPharma is currently completing an international Phase 2b clinical trial with its product ABTL0812 in patients with metastatic pancreatic cancer, a disease with a very low survival rate, with th...

AbilityPharma will secure 7 million euros with a collective investment campaign in Capital Cell of up to 2 million to finance itself until the results of its international phase 2b study in pancreatic cancer

by AbilityPharma

3 years ago
Capital Cell, AbilityPharma

The Catalan biopharmaceutical company AbilityPharma, focused on the development of innovative oral anticancer compounds, undertakes a collective investment campaign of up to 2 million on the Capital C...

SciClone joins the capital of AbilityPharma, supported by Inveready, Fitalent, Sodena and the CDTI, with an investment commitment of $3 million

by AbilityPharma

6 years ago
AbilityPharma, SciClone, Inveready, CDTI, Sodena

Carles Domènech, Executive Chairman, Chief Scientific Officer and Co-Founder of AbilityPharma, said: "We are very happy to have reached this agreement with SciClone. This investment represents a cont...

Vall d’Hebron participará en el ensayo clínico de un tratamiento contra el cáncer de páncreas

by Vall d’Hebron

6 years ago
FOLFIRINOX, ensayo clínico, cáncer de páncreas, AbilityPharma

El cáncer de páncreas afecta mayoritariamente a personas de entre 65 y 70 años y es un tumor de difícil diagnóstico y una alta mortalidad.

AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell

by AbilityPharma

6 years ago
AbilityPharma, Inveready, Capital Cell, pancreatic cancer

The Catalan biopharmaceutical company AbilityPharma, focused on the development of innovative oral anticancer compounds, undertakes the last stage of the investment round with which this year it will ...

New pathway to attack tumor cells identified

by CSIC - Centro Superior de Investigaciones Científicas

6 years ago
AbilityPharma, Autophagy, cells, cancer, stress

A study led by researchers from the Institut de Neurociències (INc-UAB), in collaboration with the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), describes a new mechanism by which the an...

Investigadores del VHIR y el IRBLleida validan el nuevo antitumoral ABTL0812 como nueva estrategia terapéutica para luchar contra el cáncer de endometrio

by AbilityPharma

7 years ago
fármaco, mujer, aparato reproductor, cáncer de endometrio, AbilityPharma

Una investigación, liderada por los Dres. Antonio Gil y Eva Colás del Vall d'Hebron Institut de Recerca (VHIR) y por los Dres. Xavier Matias-Guiu y Nuria Eritja del Instituto de Investigación Biome...

AbilityPharma cierra con Capital Cell una ronda de más de 1.230.000 euros

by AbilityPharma

8 years ago
AbilityPharma, Capital Cell, ronda de financiación

La compañía biofarmacéutica AbilityPharma acaba de cerrar una ronda de financiación por valor superior al 1.230.000 euros a través de la plataforma de crowdfunding Capital Cell. Con esta cifra...

AbilityPharma abre ronda en Capital Cell de 1 millón de euros para seguir desarrollando un fármaco que elimina células cancerosas

by AbilityPharma

8 years ago
AbilityPharma, crowdfunding, ABTL0812, autofagia, cáncer

La compañía biotecnológica AbilityPharma acaba de lanzar una ronda de inversión de 1.000.000 de euros a través de la plataforma de crowdfunding Capital Cell para seguir desarrollando ABTL0812, un...